Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Kumquat Announces $2 Billion Deal to Develop Small Molecule IO Drugs with Lilly

publication date: Jul 29, 2021

Kumquat Biosciences of San Diego announced a $2 billion agreement with a Lilly subsidiary to discover small molecule drugs that stimulate tumor-specific immune responses in cancer patients. Lilly will make a $70 million upfront payment, consisting of cash and equity, and it will be responsible for $2 billion in milestones. After Kumquat completes the discovery phase, Lilly will have an option to select the assets it will develop for the US, while Kumquat will retain China rights to the assets. Lilly will have an option to co-commercialize in China. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here